Sports and physical activity can benefit people living with hemophilia, according to a recent study. Researchers in Germany and the United Kingdom investigated to find whether participating in sports can benefit adults with varying degrees of hemophilia severity. The report, “The impact of sport on health status,…

Welcome to “Hemophilia and Me.” Former Hemophilia News Today columnist Shellye Horowitz, who wrote “The Forgotten Factor,” inspired me to dust off my journalism degree and share my own story, and now I’m grateful and honored to join a team of inspirational rock star writers. I plan…

Shire recently received marketing authorization from the European Commission for Adynovi [antihemophilic factor (recombinant) PEGylated], enabling access for adults and adolescents throughout Europe seeking treatment for hemophilia A. Adynovi is an extended half-life recombinant factor VIII for on-demand and prophylactic (preventive) use in patients 12 years and…

Children with severe hemophilia A with blood group O are not at increased risk of developing neutralizing antibodies against factor VIII (FVIII) replacement therapy, a study found. The study, “Blood Group O Does Not Increase the Risk of Inhibitors in Severe Haemophilia A: Data from the…

Despite the increasing use of preventive factor VIII (FVIII) replacement therapy, people living with hemophilia A in Japan still experience a significant disease burden, according to a recent study. Using information from health records databases, researchers found that while patients have used increasing doses and spent more on medical…

In this series of podcasts from Bloodstream Media and shared by Bloodfeed, host Patrick James Lynch submits questions about hemophilia and other bleeding disorders from listeners to various hemophilia and health care experts. MORE: The Hemophilia CHOICE Project Survey The podcasts feature a pediatric hematologist, Dr. Arash…

In the marketing world, we have a concept called the elevator pitch. An elevator pitch is a short, persuasive speech delivered in the time it takes to ride an elevator, hence the name. The goal of an elevator pitch is to quickly and effectively communicate a person’s ideas, product, or…

Shire Korea recently received approval from South Korea’s Ministry of Food and Drug Safety for Adynovate (BAX 855), a long-lasting factor VIII gene recombinant therapy for hemophilia A. Adynovate is an injectable form of Shire’s Advate, which is Korea’s most commonly used treatment for the blood disorder. Shire Korea…

One of the major hurdles people with hemophilia face is complying with their medication schedule — in particular, injecting themselves several times a week with clotting factor. MORE: Seven recommended books to learn more about hemophilia Clotting factor has a relatively short half-life (the time it takes for a person’s…

One of the major hurdles people with hemophilia face is complying with their medication schedule — in particular, injecting themselves several times a week with clotting factor. MORE: Seven recommended books to learn more about hemophilia Clotting factor has a relatively short half-life (the time it takes for a person’s…